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LETTERS TO THE EDITOR 
Anti-ASGM1, NK Cell, Activated T Cell, and Graft-vs-Host Disease 
To the Editor: 
In 1978, Korngold et al demonstrated that removal of "all mature" 
T lymphocytes by anti-Thy-1.2 and complement was very effective 
in preventing the development of significant graft-vs-host disease 
(GVHD) in mice [1]. However, implementation of this strategy in 
patients using OKT3 failed to achieve similar impressive results [2]. 
Having learned of the work of Lopez who demonstrated that the 
severity of GVHD in man was closely related to initial NK activity 
of the recipients [3], Charley and his colleagues began investigating 
the effect of anti-asialo GMI (aASGMl), an antiserum believed to 
be NK-specific, on the incidence and severity of GVHD in mice 
recipients and found the antiserum to be highly effective in pre-
venting lethal (but not all) GVHD [4]. 
However, they later found aASGMl to be nonspecific for NK 
cells [5], and the mechanism by which aASGMl prevented lethal 
GVHD was, in fact, related to its ability to bind and extinguish T 
cells which ·became activated after transplantation [6]. This latter 
finding confirms that T cells are vital to the development of signifi-
cant GVHD in human, as well as in murine model. 
To explain these seemingly contradictory findings, it is necessary 
to explore the technics employed to remove T cells and to under-
stand the various surface antigens involved. 
Korngold et al used anti-Thy-l.2 and complement to remove "all 
mature" T cells [1]. Since Thy-l is the first surface antigen ex-
pressed on the surface of murine T lymphocytes, immature T cells 
and possibly some other noncommitted hematopoietic precursors 
are also removed by this technic. On the contrary, T3 (recognized 
by OKT3) appears on the surface relatively late in the ontogeny ofT 
lymphocytes [7] . OKT3 therefore removes only more-mature 
forms ofT cells. As demonstrated by Korngold, that contamination 
of the graft by as few as 0.3% T cells was enough to cause a high 
incidence of lethal GVHD [1]. It is thus not surprising why Filopo-
vich et al failed to achieve a result comparable to that reported in the 
murine experiment. 
Depletion ofT lymphocytes by sequential use of soybean agglu-
tinin and differential sedimentation of sheep E-rosette forming cells 
[8] is a different approach because the sheep RBC recer.tor, TIl 
antigen, is the first to be expressed on T cell surface 171. More 
importantly, this receptor had been shown to facilitate T lympho-
cyte-target cell interactions and to activate resting T cells indepen-
dently of a specific antigen and the MHC [9]. This method can 
therefore achieve a.better result as experienced by Reisner et ai, since 
more of the immature forms are also removed. 
Both OKT11 and aASGM 1 can be very useful in the prevention 
of significant GVHD in patients undergoing bone-marrow trans-
plantation and deserve further attention. Monoclonal antibodies 
have been increasingly useful both as a probe and as a therapeutic 
agent. New antibodies are continuously introduced at a very rapid 
pace. It is therefore imperative to understand their power and limi-
tation. Inference from finding of study using monoclonal antibodies 
should be made with great caution. 
Suchai Sriprachya-anunt, M.D. 
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REPLY 
Dr. Sriprachya-anunt's letter cautions against extrapolating murine 
experimental results too readily to the human situation. We cer-
tainly concur that only additional investigations will determine 
whether the use of antibodies against asialo-GM 1 may be applicable 
in human bone marrow transplantation to prevent GVHD. How-
ever, we cannot resist a further speculation, with the same caveat 
noted. 
Recent findings of Murphy, Kumar and Bennett have conclu-
sively implicated both mouse NK cells and T lymphocytes in the 
rejection of donor marrow [1,2]. Because asialo GMt is constitu-
tively expressed on NK cells and becomes expressed on activated T 
cells, it is possible that administration of anti-asialo GM t will simul-
taneously prevent GVHD and marrow rejection. 
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